Posted by Michael Wonder on 09 Mar 2023
CADTH recommends reimbursement for BioCryst’s Orladeyo (berotralstat) for the routine prevention of attacks in hereditary angioedema patients in Canada
8 March 2023 - BioCryst Pharmaceuticals today announced that the CADTH Canadian Drug Expert Committee has issued a positive recommendation for Orladeyo (berotralstat) to be reimbursed for the routine prevention of attacks of hereditary angioedema in adults and paediatric patients 12 years of age and older.
Health Canada authorised Orladeyo in June 2022 for the routine prevention of recurrent hereditary angioedema attacks in patients 12 years and older.
